Cullinan Oncology (NASDAQ:CGEM – Get Free Report) and Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, profitability, risk and earnings.
Earnings and Valuation
This table compares Cullinan Oncology and Titan Pharmaceuticals’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cullinan Oncology | $18.94 million | 24.59 | $111.21 million | ($3.37) | -3.23 |
| Titan Pharmaceuticals | $560,000.00 | 14.75 | -$10.21 million | N/A | N/A |
Cullinan Oncology has higher revenue and earnings than Titan Pharmaceuticals.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cullinan Oncology | 0 | 0 | 4 | 0 | 3.00 |
| Titan Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Cullinan Oncology presently has a consensus target price of $26.50, suggesting a potential upside of 143.12%. Given Cullinan Oncology’s higher possible upside, research analysts clearly believe Cullinan Oncology is more favorable than Titan Pharmaceuticals.
Insider and Institutional Ownership
81.8% of Cullinan Oncology shares are held by institutional investors. Comparatively, 6.3% of Titan Pharmaceuticals shares are held by institutional investors. 8.8% of Cullinan Oncology shares are held by company insiders. Comparatively, 27.9% of Titan Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
Cullinan Oncology has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.
Profitability
This table compares Cullinan Oncology and Titan Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cullinan Oncology | N/A | -26.92% | -25.60% |
| Titan Pharmaceuticals | -2,137.63% | -949.26% | -254.32% |
Summary
Cullinan Oncology beats Titan Pharmaceuticals on 9 of the 11 factors compared between the two stocks.
About Cullinan Oncology
Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
